May. 13 at 3:33 PM
$IFRX What I find interesting now is that IFRX and Izicopan are no longer only appearing on stock market or biotech websites, but are now also being discussed on specialized AAV/patient platforms like ANCA Vasculitis News. To me, this shows that the story is slowly reaching the actual patient and disease community as well.
What stood out to me there was that severe kidney patients were specifically mentioned together with the strong focus on safety and efficacy measurements. Severe kidney involvement is considered one of the most critical situations in AAV, so this point could be especially relevant for patients and treating physicians.
The strong safety focus also does not seem random at all in the current Tavneos environment. Statements like “safer, faster and more convenient alternative” were also surprisingly open and confident in my opinion. Overall, I found it remarkable how concretely the topic is already being discussed there.
https://ancavasculitisnews.com/news/phase-2-trial-planned-test-izicopan-aav/
